HUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $15.58, but opened at $15.18. HUTCHMED shares last traded at $14.85, with a volume of 12,786 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.

HUTCHMED Stock Down 4.4 %

The company has a 50 day moving average of $18.42 and a 200 day moving average of $18.25. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its holdings in shares of HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock worth $129,000 after purchasing an additional 564 shares during the period. M&G PLC boosted its position in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after buying an additional 132,333 shares during the last quarter. Blue Trust Inc. grew its stake in shares of HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock valued at $69,000 after acquiring an additional 3,057 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of HUTCHMED by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company's stock worth $1,060,000 after acquiring an additional 4,877 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of HUTCHMED by 74.8% during the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock worth $2,248,000 after buying an additional 56,200 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.